Sunday, March 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Antimicrobial Resistance

BARDA Funds Countermeasure for Burkholderia Infections

by Global Biodefense Staff
February 6, 2014
Burkholderia pseudomallei
Burkholderia pseudomallei is a NIAID Category B Priority Pathogen for Biodefense. Image source: DTRA

A new drug to help protect the public against two bioterrorism threats and provide a new option to treat antibiotic-resistant infections will advance in development under a public-private partnership, the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) announced this week.

“Antibiotic resistance adversely impacts our nation’s ability to respond effectively to a bioterrorism attack and to everyday public health threats,” said Robin Robinson, Ph.D., director of ASPR’s Biomedical Advanced Research and Development Authority (BARDA), which will oversee the project. “By partnering with industry to develop novel antimicrobial drugs against biothreats that also treat drug-resistant bacteria, we can address health security and public health needs efficiently.”

BARDA will support the development of Carbavance under a five-year cost-sharing agreement with Rempex Pharmaceuticals Inc. (a wholly owned subsidiary of The Medicines Company) in San Diego. The agreement includes an initial commitment from BARDA of $19.8 million and can be extended to provide up to $90 million over the five years.

The two bioterrorism threats are melioidosis and glanders. With existing antibiotic treatments, approximately 40 percent of people who become ill from these bacteria die from the illness, and up to 90 percent die if not treated.

Melioidosis, also called Whitmore’s disease, can be mistaken for other diseases such as tuberculosis and common forms of pneumonia. Melioidosis is caused by a Gram-negative bacterium, Burkholderia pseudomallei, found in soil and water. The bacteria can cause infection when a person touches or inhales the bacteria. The infection is common in parts of Southeast Asia and northern Australia.

Glanders is a respiratory disease that can affect people, although it is primarily found in animals. The bacteria that cause glanders, Burkholderia mallei, can affect skin, blood, lungs, or muscles, and may be transmitted through direct contact with infected animals or by inhaling contaminated aerosols or dust.

Melioidosis and glanders can become resistant to existing antibiotics.

In addition to showing promise as a treatment for melioidosis and glanders in a bioterrorism event, Carbavance potentially could be used commercially to treat complicated urinary tract infections, hospital-acquired pneumonia, ventilator-acquired pneumonia, and carbapenem-resistant Enterobacteriaceae (CRE), all of which can be resistant to existing antibiotics.

CRE are a family of bacteria that have been called nightmare bacteria because the bacteria are resistant to all or nearly all antibiotics, kill up to half of people who get serious infections with them, and can spread their resistance to other bacteria. CRE infections have been detected in nearly every state, and the incidence has risen sharply over the past five years.

Patients whose care requires devices such as ventilators, urinary (bladder) catheters, or intravenous (vein) catheters, and patients who are taking long courses of certain antibiotics are most at risk for CRE infections.

The project includes preclinical and clinical studies, manufacture of enough of the drug for clinical studies, and other manufacturing-related activities needed to apply for U.S. Food and Drug Administration approval of the drug.

The project with Rempex is the latest in a BARDA program that supports development of broad-spectrum antimicrobials, technologies and platforms for biodefense needs that simultaneously address other public health challenges, such antibiotic-resistant infections.

BARDA is seeking additional proposals for advanced development of novel antimicrobials to treat illness caused by biological threat agents and that also could address the growing threat of antimicrobial resistance. Proposals are accepted through the Broad Agency Announcement BARDA-BAA-13-100-SOL-00013.

Source: HHS.gov

Tags: AntimicrobialsASPRBAABARDABioterrorismBurkholderiaHHS

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC